The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients | Zendy

Kamila WojasKrawczyk | Zendy; Paweł Krawczyk | Zendy; Radosław Mlak | Zendy; Tomasz Kucharczyk | Zendy; Dariusz M. Kowalski | Zendy; Maciej Krzakowski | Zendy; Janusz Milanowski | Zendy

Open Access

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

Author(s) -

Kamila WojasKrawczyk,

Paweł Krawczyk,

Radosław Mlak,

Tomasz Kucharczyk,

Dariusz M. Kowalski,

Maciej Krzakowski,

Janusz Milanowski

Publication year - 2011

Publication title -

respiration

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.264

H-Index - 81

eISSN - 1423-0356

pISSN - 0025-7931

DOI - 10.1159/000322843

Subject(s) - medicine , erlotinib , lung cancer , proportional hazards model , oncology , performance status , gefitinib , rash , erlotinib hydrochloride , chemotherapy , cancer , epidermal growth factor receptor

Tyrosine kinase inhibitors of EGFR (TKI-EGFR) induced response in only 10% of Caucasian non-small-cell lung cancer patients in second- or third-line treatment. Independent predictive factors for qualification to TKI-EGFR treatment have not been assessed. In 2008, a prognostic index was reported for patients treated with erlotinib in the BR.21 trial, but its application for real, unselected patients is limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research